Skip to main content

Table 5 Best overall tumor response

From: A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

Best overall response

huKS-IL2 dosing cohort, mg/m2

 

0.5

1.0

2.0

3.0

4.0

Overall

(n=3)

(n=4)

(n=6)

(n=6)

(n=7)

(n=26)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (missing)

3 (0)

3 (1)

6 (0)

6 (0)

7 (0)

25 (1)

CR

0

0

0

0

0

0

PR

0

0

0

0

0

0

SD

1 (33.3)

1 (33.3)

2 (33.3)

3 (50.0)

3 (42.9)

10 (40.0)

PD

2 (66.7)

2 (66.7)

4 (66.7)

2 (33.3)

4 (57.1)

14 (56.0)

  1. Notes: Includes subjects who withdrew due to PD prior to an objective tumor response assessment. One subject discontinued the study due to treatment-emergent adverse events without any post-baseline disease assessment.
  2. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.